吉林敖東(000623.SZ):注射用核糖核酸Ⅱ預計未來市場份額將逐漸恢復
格隆匯7月4日丨吉林敖東(000623.SZ)接受機構調研時表示,2023年1月13日,國家衞健委公佈《第二批國家重點監控合理用藥藥品目錄》,公司產品注射用核糖核酸Ⅱ被調整出重點監控目錄。注射用核糖核酸Ⅱ為免疫調節藥物,適用於胰腺癌、肝癌、胃癌、肺癌、乳腺癌、軟組織肉瘤及其他癌症的輔助治療,對乙型肝炎的輔助治療有較好的效果。本品亦可用於其他免疫機能低下引起的各種疾病。對術後修復、放化療後修復有着顯著療效,可以提高身體的免疫力。同時注射用核糖核酸Ⅱ因其確切的療效,入選《臨牀路徑治療藥物釋義》,預計未來市場份額將逐漸恢復。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.